Baidu
map

NAT MED:迄今为止很大的阿兹海默症相关蛋白研究发表

2020-04-14 MedSci原创 MedSci原创

最近,研究人员利用定量质谱和共表达网络分析,对AD进行了迄今为止最大的蛋白质组学研究。

至今为止,我们对于阿尔茨海默氏病(AD)病理生理学的理解仍然不完整。

最近,研究人员利用定量质谱和共表达网络分析,对AD进行了迄今为止最大的蛋白质组学研究。

研究人员发现了一个与糖代谢相关的蛋白质网络模块,其作为与AD病理和认知障碍最显著相关的模块之一。该模块富集了AD遗传危险因素以及与抗炎状态相关的小胶质细胞和星形胶质细胞蛋白标记物,表明其代表的生物功能在AD中起保护作用。

在该病的早期阶段,该模块的蛋白质在脑脊液中升高。

在这项通过定量蛋白质组学对>2000个大脑和近400个脑脊液样本的研究中,研究人员确定了AD脑中的蛋白质和生物过程,这些蛋白质和生物过程可能作为该病的治疗靶点和脑脊液生物标志物。

 

原始出处:

Erik C. B. Johnson et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020; 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=946322, encodeId=4f7194632288, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78f72514592, createdName=海1991, createdTime=Mon Mar 08 10:31:24 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884244, encodeId=11551884244c5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 25 15:04:52 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465356, encodeId=0f5b146535664, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610430, encodeId=6cf81610430ae, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2021-03-08 海1991

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=946322, encodeId=4f7194632288, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78f72514592, createdName=海1991, createdTime=Mon Mar 08 10:31:24 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884244, encodeId=11551884244c5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 25 15:04:52 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465356, encodeId=0f5b146535664, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610430, encodeId=6cf81610430ae, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=946322, encodeId=4f7194632288, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78f72514592, createdName=海1991, createdTime=Mon Mar 08 10:31:24 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884244, encodeId=11551884244c5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 25 15:04:52 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465356, encodeId=0f5b146535664, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610430, encodeId=6cf81610430ae, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=946322, encodeId=4f7194632288, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78f72514592, createdName=海1991, createdTime=Mon Mar 08 10:31:24 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884244, encodeId=11551884244c5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 25 15:04:52 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465356, encodeId=0f5b146535664, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610430, encodeId=6cf81610430ae, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 16 06:04:52 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-04-16 智慧医人

相关资讯

细数免疫治疗的“直系及旁系亲属们”

免疫治疗已被证明在多种癌症中发挥重要的抗肿瘤效应,尽管CTLA4和PD-L1/PD-1抗体已在临床试验中取得成功,但仅有小部分患者表现持久性的临床应答,表明现阶段对于癌症免疫仍然需要更为广泛的认识。

Nat Commun:血液生物标记物或有助于预测死亡风险

《自然-通讯》发表的一篇论文A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals 报道了14种与全因死亡率相关的血液生物标记物。相较于目前已有的方法,这项最新发现或有助于提高5年及10年死亡风险的预测准确性。

肿瘤免疫治疗疗效预测生物标记物,尚有多远?

肿瘤免疫治疗对于肿瘤治疗领域具有划时代的意义,不仅仅是在肿瘤治疗上增添了一种全新的治疗手段(目前是手术、放疗、化疗、靶向治疗),而是开辟了一个抗肿瘤的新纪元:从直接杀伤肿瘤细胞转为通过调节患者自身免疫

CLIN CHEM LAB MED:临床生物标记物的创新?

选择用于进一步研究和开发的生物标志物检测,不仅关系到诊断的准确性,而且关系到后续的临床和经济效益。

Clin Chem:临床研究中使用的生物标记物的分析特征报告不足?

测量生物标志物的方法的分析特征决定了这些方法的测量过程及测量结果。因此,分析特征的透明报告使读者能够评估使用生物标志物的临床研究的有效性和普遍性。我们的目的是评估临床研究中使用的生物标志物的分析特征的报告,并评估已报告的用于测定精度的鉴定程序的范围。

J Rheumatol:既往无心脏病SLE患者的心脏生物标记物异常

在无既往心脏病或PAH的情况下,约10%的SLE患者心肌生物标记物升高。

Baidu
map
Baidu
map
Baidu
map